ECSP003792A - Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida - Google Patents

Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida

Info

Publication number
ECSP003792A
ECSP003792A EC2000003792A ECSP003792A ECSP003792A EC SP003792 A ECSP003792 A EC SP003792A EC 2000003792 A EC2000003792 A EC 2000003792A EC SP003792 A ECSP003792 A EC SP003792A EC SP003792 A ECSP003792 A EC SP003792A
Authority
EC
Ecuador
Prior art keywords
carboxamino
tetrahydroquinoline
crystal
replaced
crystals
Prior art date
Application number
EC2000003792A
Other languages
English (en)
Spanish (es)
Inventor
Derek Lawrence Tickner
Lyle R Brostrom
Troy Anthony Appleton
Allen Douglas John Meldrum
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP003792A publication Critical patent/ECSP003792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
EC2000003792A 1999-11-30 2000-11-29 Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida ECSP003792A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
ECSP003792A true ECSP003792A (es) 2002-04-23

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003792A ECSP003792A (es) 1999-11-30 2000-11-29 Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida

Country Status (28)

Country Link
EP (1) EP1246804A1 (fr)
JP (1) JP2003515592A (fr)
KR (1) KR20020058057A (fr)
CN (1) CN1402711A (fr)
AP (1) AP2002002531A0 (fr)
AU (1) AU1048801A (fr)
BG (1) BG106854A (fr)
BR (1) BR0015836A (fr)
CA (1) CA2392979A1 (fr)
CO (1) CO5271716A1 (fr)
EA (1) EA200200510A1 (fr)
EC (1) ECSP003792A (fr)
EE (1) EE200200277A (fr)
GT (1) GT200000199A (fr)
HU (1) HUP0203521A2 (fr)
IL (1) IL149097A0 (fr)
IS (1) IS6338A (fr)
MA (1) MA26845A1 (fr)
MX (1) MXPA02005354A (fr)
NO (1) NO20022558D0 (fr)
OA (1) OA12099A (fr)
PA (1) PA8506301A1 (fr)
PE (1) PE20010904A1 (fr)
PL (1) PL355892A1 (fr)
TN (1) TNSN00231A1 (fr)
TR (1) TR200201446T2 (fr)
UY (1) UY26454A1 (fr)
WO (1) WO2001040190A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EA200301139A1 (ru) 2001-06-21 2004-12-30 Пфайзер Продактс Инк. Самоэмульгирующиеся препараты ингибиторов белка-переносчика эфиров холестерина
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1920766B1 (fr) * 2002-02-01 2017-08-23 Bend Research, Inc Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004032848A2 (fr) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Antagonistes vis-a-vis du recepteur pgd2 pour le traitement de maladies inflammatoires
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
WO2004082675A1 (fr) 2003-03-17 2004-09-30 Japan Tobacco Inc. Procede pour accroitre la biodisponibilite orale de s- [2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] -2-methylpropanethioate
JP2006521344A (ja) * 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
DE602004023100D1 (de) 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
CA2562082C (fr) * 2004-04-13 2013-06-25 Merck & Co., Inc. Inhibiteurs de la cetp pour le traitement et la prevention de l'atherosclerose
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
WO2006033004A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline en tant qu'inhibiteurs de cetp
WO2006033001A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline
WO2006091674A1 (fr) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
MX384679B (es) 2014-07-30 2025-03-14 Hoffmann La Roche Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
NO20022558L (no) 2002-05-29
EA200200510A1 (ru) 2002-10-31
WO2001040190A1 (fr) 2001-06-07
BR0015836A (pt) 2002-08-06
BG106854A (bg) 2002-12-29
IS6338A (is) 2002-04-12
JP2003515592A (ja) 2003-05-07
PL355892A1 (en) 2004-05-31
KR20020058057A (ko) 2002-07-12
OA12099A (en) 2006-05-04
CO5271716A1 (es) 2003-04-30
UY26454A1 (es) 2001-07-31
AU1048801A (en) 2001-06-12
HUP0203521A2 (hu) 2003-02-28
NO20022558D0 (no) 2002-05-29
PE20010904A1 (es) 2001-09-10
EE200200277A (et) 2003-10-15
GT200000199A (es) 2002-05-23
TR200201446T2 (tr) 2002-11-21
MA26845A1 (fr) 2004-12-20
EP1246804A1 (fr) 2002-10-09
MXPA02005354A (es) 2002-12-11
AP2002002531A0 (en) 2002-06-30
CA2392979A1 (fr) 2001-06-07
TNSN00231A1 (fr) 2002-05-30
IL149097A0 (en) 2002-11-10
CN1402711A (zh) 2003-03-12
PA8506301A1 (es) 2002-08-26

Similar Documents

Publication Publication Date Title
ECSP003792A (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
UY24555A1 (es) Nuevos compuestos
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
DK1007520T3 (da) 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
ES2133543T3 (es) Derivados de pirrolidina y oxazolidina, su preparacion y su uso como inhibidores de la agregacion de trombocitos.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
NO934628L (no) Retrovirus-protease-inhibitorer
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR028443A1 (es) Nuevos compuestos derivados de piperazina y piperidina, metodo para su preparacion, composiciones farmaceuticas que los contienen y preparacion de las mismas y uso de dichos compuestos
ES2177656T3 (es) Derivados de antraciclinona y su utilizacion en el tratamiento de la amiloidosis.
HN2001000235A (es) Derivados puentes de piperazina
DK1051177T3 (da) Steroide 3-O-Sulfamatderivater som inhibitorer af östronsulfatase
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
MX9603092A (es) Nuevos compuestos con efecto analgesico y anestesico local.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2186989T3 (es) Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion.
MX9601635A (es) Derivados de antraciclina.
PA8495001A1 (es) Nuevas formas cristalinas de un antibiotico macrolido.
AR002978A1 (es) Compuestos benzamidas, composiciones farmacéuticasque los contienen, metodos para preparar los mismos y el uso de los mismos.
MX9303574A (es) Compuestos heterociclicos que son inhibidores de la enzima aromatasa, proceso para su preparacion ycomposiciones farmaceuticas que los contienen.